AREVA Med’s Phase 1 Clinical Trial with Lead-212
Preliminary Results Are Now Available
In 2012, AREVA Med launched the first Phase 1 clinical trial of 212Pb-TCMC-trastuzumab, aimed at combating intra-abdominal HER-2 expressing cancers. The preliminary results of this study were published in the Journal of Nuclear Medicine in October 2014.
Dose Escalation and Dosimetry of First-in-Human Alpha Radioimmunotherapy with 212Pb-TCMC-Trastuzumab
Purpose: Study the safety, distribution, pharmacokinetics, immunogenicity, and tumor response of intraperitoneal 212Pb-TCMC-trastuzumab in patients with human epidermal growth factor receptor type 2 (HER-2)-expressing malignancy.
Results & Conclusions: Five dosage levels (from 7.4 to 21.1 MBq/m2) showed minimal toxicity at more than one year for the first group and more than four months for subsequent groups. The lack of substantial toxicity was consistent with the dosimetry assessments.
For the full article, please visit the Journal of Nuclear Medicine: http://jnm.snmjournals.org/content/early/2014/08/25/jnumed.114.143842